{
  "nct_id": "NCT00607633",
  "title": "Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH",
  "conditions": [
    "Essential Hypertension",
    "Left Ventricular Hypertrophy"
  ],
  "interventions": [],
  "phase": "N/A",
  "summary": "The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..",
  "source": "clinicaltrials.gov",
  "collected_at": "2026-01-07T20:03:08.377772"
}